JPMorgan Chase & Co. reaffirmed their overweight rating on shares of AstraZeneca (LON:AZN) in a research report report published on Monday morning, Borsen Zeitung reports. They currently have a GBX 7,900 ($103.23) price target on the biopharmaceutical company’s stock.
Several other equities analysts have also issued reports on AZN. Credit Suisse Group set a GBX 7,300 ($95.39) target price on AstraZeneca and gave the stock a buy rating in a research report on Friday, July 26th. Citigroup restated a buy rating and set a £100 ($130.67) target price (up from GBX 7,000 ($91.47)) on shares of AstraZeneca in a research report on Wednesday, September 11th. Societe Generale restated a buy rating on shares of AstraZeneca in a research report on Tuesday, September 10th. Barclays boosted their target price on AstraZeneca from GBX 8,000 ($104.53) to GBX 8,200 ($107.15) and gave the stock an overweight rating in a research report on Friday, September 13th. Finally, Goldman Sachs Group set a GBX 5,500 ($71.87) target price on AstraZeneca and gave the stock a sell rating in a research report on Monday, September 2nd. Three equities research analysts have rated the stock with a sell rating, six have given a hold rating and nine have assigned a buy rating to the company. The company has a consensus rating of Hold and a consensus price target of GBX 7,050 ($92.12).
AstraZeneca stock opened at GBX 7,127 ($93.13) on Monday. The firm has a market capitalization of $93.50 billion and a P/E ratio of 41.63. AstraZeneca has a 1 year low of GBX 5,312 ($69.41) and a 1 year high of GBX 7,583 ($99.09). The business has a 50-day moving average of GBX 7,186.15 and a 200-day moving average of GBX 6,411.05. The company has a current ratio of 0.95, a quick ratio of 0.74 and a debt-to-equity ratio of 144.48.
AstraZeneca PLC discovers, develops, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, autoimmunity, infection, neuroscience, and gastroenterology worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor, Plendil, Seloken/Toprol-XL, Tenormin, and Zestril for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.
Further Reading: Mutual Funds
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.